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Abstract
The human immunodeficiency virus type 1 (HIV-1) has been intensely investigated since its
discovery in 1983 as the cause of acquired immune deficiency syndrome (AIDS). With relatively
few proteins made by the virus, it is able to accomplish many tasks, with each protein serving
multiple functions. The Envelope glycoprotein, composed of the two noncovalently linked subunits,
SU (surface glycoprotein) and TM (transmembrane glycoprotein) is largely responsible for host cell
recognition and entry respectively. While the roles of the N-terminal residues of TM is well
established as a fusion pore and anchor for Env into cell membranes, the role of the C-terminus of
the protein is not well understood and is fiercely debated. This review gathers information on TM
in an attempt to shed some light on the functional regions of this protein.
Review
HIV discovery and clinical presentation
In 1981 the CDC (USA) began noting a group of homo-
sexual men presenting with symptoms of a rare opportun-
istic infections at a San Francisco clinic [1,2]. These
patients were later found to be suffering from severe
immune deficiency and their syndrome was dubbed
acquired immune deficiency syndrome (AIDS). In 1983,
two viruses were simultaneously isolated in the United
States and France thought to be the cause of these infec-
tions, named HTLV-III (Human T Lymphotropic Virus)
and LAV (Lymphadenopathy Associated Virus) respec-
tively [3-8]. HTLV-III and LAV, along with a third virus
isolated from AIDS patients in San Francisco, named ARV
for AIDS-associated Retrovirus [9] were later discovered to
be the same virus and renamed Human Immunodefi-
ciency Virus, or HIV [10].
Since its discovery it has been estimated that more than
64.9 million people have been infected with HIV world-
wide, with greater than 32 million AIDS-related deaths
(refer to [222]. Infection with HIV is characterized by
three clinical stages – acute viremia, a latency phase of var-
iable duration, and a classification of clinical AIDS (Figure
1). Concurrent with initial infection, virus can be detected
in the blood of patients [11,12]. After the initial viremia
peaks, the level of virus in the blood falls off and a phase
of "latency" ensues. During the latency phase, HIV load is
generally very low to non-detectable, though there is a
high turnover of CD4+ T cells and HIV virion production
[13-17]. Before the advent of highly active antiretroviral
therapy (haart), it was established that the levels of virus
in the blood at this stage are negatively correlated with
prognosis and time course of progression to AIDS [17-19].
It is during the latency phase that CD4+ T cell counts also
begin to decline and an inversion of the CD4+/CD8+ T cell
ratio occurs. A CD4+ T cell count below 200 cells/mm3
and infection with at least one opportunistic infection,
such as Pneumocystis Carinii defines clinical AIDS. It is at
this final stage where patients' immune systems are no
longer able to function properly and patients eventually
succumb to their secondary infections, to otherwise rare
cancers (such as Kaposi's sarcoma) or to other manifesta-
tions of HIV infection (such as neuropathy).
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HIV classification, structure, genome, and replication cycle
HIV is enveloped, contains reverse transcriptase and 2
identical copies of a positive sense, linear RNA genome
(Figure 2). HIV is classified in a subgroup of retroviruses
called the lentiviridae based on these "morphological,
genetic, and biological properties" [10,20]. HIV is a slow
virus – the clinical "latency" phase can last more than 20
years. During this time, HIV can have widespread effects
on immunological and neurological systems. Lentiviruses
are known for their cytolytic and immunosuppressive
properties and include viruses such as simian immunode-
ficiency virus (SIV), feline immunodeficiency virus (FIV),
caprine arthritis-encephalitis virus (CAEV), and equine
infectious anemia virus (EIAV).
As with all lentiviruses, HIV possesses a complex genome
(in this case, 9.8 kb) containing accessory and regulatory
genes (Figure 3). An additional, novel open reading
frame, vpu separates the pol and env regions [10,21]. In
total 9 genes are present that can be classified into 3 func-
tional groups. Gag, Pol, and Env are structural genes; Tat
and Rev are regulatory genes; Vpu, Vpr, Vif, and Nef are
accessory genes. A general overview of the replication
cycle in a single cell is presented in Figure 4. After direct
fusion of the virion and cellular lipid membranes, the
viral core is released into the cytoplasm where it uncoats
and releases the RNA genome. The viral genome is then
reverse transcribed and transported to the nucleus where
it integrates as a provirus. The early gene products, tat, rev,
and nef are first transcribed, followed later by the rest of
the HIV genome. Assembly and budding of progeny viri-
ons takes place at the plasma membrane.
Gag codes for the capsid protein which recruits two copies
of the RNA genome, the pol gene products (reverse tran-
scriptase, protease, and integrase), and other viral and cel-
lular gene products to the plasma membrane for budding
of the virus. Env encodes the Envelope protein, or Env,
which is synthesized as a single polyprotein in the endo-
plasmic reticulum. After synthesis, Env (gp160) is heavily
glycosylated in the Golgi complex before a cellular pro-
tease cleaves it into the noncovalently associated proteins,
surface glycoprotein (SU, or gp120) and transmembrane
glycoprotein (TM, or gp41).
SU is an extracellular protein which primarily functions to
recognize HIV's primary and secondary cellular receptors,
CD4 and CCR5/CXCR4 respectively on target cells [22].
Analysis of the expression of these receptors in immune
cells is sufficient to explain the tropism of HIV, primarily
macrophages and T lymphocytes. TM on the other hand
HIV genome and replication cycle Figure 3
HIV genome and replication cycle. Depiction of the ~10 
Kb HIV-1 genome showing the organization of genes and 
their transcriptional splicing (dashed lines). Relevant TM 
domains are highlighted.
Time course of HIV infection Figure 1
Time course of HIV infection. Time course of HIV infec-
tion showing correlation of viral load, CD4+ T cell, and CD8+ 
T cell counts.
The HIV-1 virion Figure 2
The HIV-1 virion. Graphical depiction of the HIV-1 virion. 
Vpu is not thought to be present in the virion in any appreci-
able amount.Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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appears to function in membrane interactions. It is an
integral membrane protein which contains a transmem-
brane anchor domain that anchors Env into the lipid
membrane [10]. TM is responsible for fusion of the viral
and cellular membranes via its fusion peptide located in
TM's extracellular, N-terminal domain. The fusion pep-
tide of HIV-1 has shown some structural and functional
similarities to the hydrophobic internal region of bovine
prion protein (BPrPtm) [23]. Both of these peptides are
notable for their ability to interact with, and insert into
membranes. After the addition of calcium, there is a shift
in conformation from α-helix to β-sheet which accompa-
nies membrane fusion. The C-terminal, cytoplasmic tail
of TM is known to help direct the assembly of virions at
the cell surface [24], among other functions (see below).
The regulatory proteins, Tat and Rev are both RNA bind-
ing proteins. Tat is an RNA binding protein and transcrip-
tional activator that works to ensure full length HIV
genomes are produced [25]. Tat is also known to activate
cellular genes such as TNF-β and TGF-β as well as down-
regulate the expression of other cellular genes such as bcl-
2 and MIP1-α. HIV's other regulatory protein, Rev, is an
RNA binding protein that is required for the transition of
HIV gene expression from the early phase to the late phase
[26]. Rev accomplishes this through binding of unspliced
or incompletely spliced viral RNA's in the nucleus and
nucleolus and then transporting them into the cytoplasm,
leaving fewer viral RNA's to be completely spliced.
The accessory proteins coded in the HIV genome are
known to be multifunctional. Nef, or negative factor, has
been shown to downregulate existing CD4 and MHC I
expression at the cell surface via degradation in lysosomes
[27,28]. Nef can perturb T cell activation (up- or down-
regulate) and stimulate HIV virion infectivity. Nef shows
sequence and structural features of scorpion peptides
known to interact with K+ channels. When Nef is added to
chick dorsal root ganglion an increase in K+ current is
observed [29]. Vpr allows HIV to infect nondividing cells
by acting as a nucleocytoplasmic transport factor [30]. Vpr
has reported cation-selective ion channel activity in planar
lipid bilayers [31]. Vpr "pores" may be active in both
nuclear and mitochondrial membranes [32-34]. In the
nuclear membrane, Vpr may facilitate the translocation of
the HIV-1 preintegration complex from the cytoplasm to
the nucleus. In mitochondrial membranes, Vpr binds to
the adenine nucleotide translocase (ANT), part of the
mitochondrial permeability transition pore (MPTP).
Binding of Vpr to ANT can convert it to a pro-apoptotic
pore, leading to uncoupling of mitochondrial respiration,
loss of transmembrane potential, swelling of the matrix,
and release of intermembrane proteins. Additionally, Vpr
acts to arrest the cell cycle in the G2 phase, preventing
entry into mitosis [35]. The internal membrane localized
Vpu functions to downmodulate CD4 expression via
ubiquitin-mediated degradation and to enhance virion
release through the formation of an ion channel which
collapses membrane potential and may promote virion
release (discussed in greater depth below) [27]. Finally,
Vif is essential for the replication of HIV in PBMC's, lym-
phocytes, macrophages, and certain cell lines suggesting
that it may act through interaction with a cellular factor
that is host species specific [26].
HIV cytopathology and induced ion modifications
Selective depletion of CD4+ T cells is a hallmark of HIV
infection and is accomplished, at least in part, due to
direct cytopathic effects (CPE) of the virus [36]. The HIV
replication cycle is complex and not completely under-
stood. It is increasingly thought to begin via interaction
with dendritic cells during transmission [37]. A protein
present on dendritic cells, DC-SIGN, reversibly binds HIV,
with or without internalizing it, and shuttles it to a
regional lymph node, thought to be the primary site for
Overview of the replication cycle of HIV-1 Figure 4
Overview of the replication cycle of HIV-1. Overview 
of some of the basic steps of HIV infection of a cell.Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
Page 4 of 22
(page number not for citation purposes)
replication and spread of HIV. When the virus encounters
a macrophage or T cell with its primary CD4 receptor and
a coreceptor, either CXCR4 or CCR5, conformational
changes caused by the binding of SU expose the fusion
peptide of TM triggering direct fusion of the HIV and host
cell membranes. CD4 is expressed on many cells in the
body, but is found in highest levels on T lymphocytes,
macrophages, and in the brain, primarily astrocytes [38].
The specificity for the coreceptor is determined by the V3
loop region of SU and explains the tropism of the virus for
specific cell types [39]. CCR5-utilizing HIV (macrophage
tropic, non-syncytium inducing) strains are preferentially
transmitted over CXCR4-utilizing (T cell tropic, syncy-
tium inducing) strains for reasons that are not completely
understood [40,41]. A naturally occurring ΔCCR5 muta-
tion in humans correlates with resistance to infection by
HIV [42]. The emergence of CXCR4 strains during the
course of an infection is correlated with increased CD4+ T
cell depletion and accelerated progression towards AIDS
[43]. This increase in T cell depletion can at least be par-
tially explained by the fact that a higher percentage of T
cells express CXCR4 (90–100%) than express CCR5 (10–
30%) [44,45] and suggests a role for direct cytopathic
effect by HIV.
The ability to directly lyse CD4+ T cells have been postu-
lated to at least partially cause the reduction of these
immune effecter cells which leads to the clinical condition
of AIDS. Three additional mechanisms have been postu-
lated for CD4+ T cell depletion including immune destruc-
tion of infected cells, apoptosis, and impaired lymphocyte
regeneration. These alternative mechanisms for in vivo
CD+ T cell depletion are reviewed in McMichael et al.,
2000, Alimonti et al., 2003, and Douek et al., 2003 respec-
tively [46-48]. The relative contribution of each of these
mechanisms, if any, is still not clear. However, there is
strong evidence that direct cytopathic effects of the virus
play a large role in its pathogenicity.
Only cells expressing CD4 along with the proper corecep-
tor are infected by HIV [38,49]. HIV kills cells in cell cul-
ture as well as in vivo. Through the course of natural
disease, the virus switches use of coreceptors from the less
cytopathic CCR5 (R5), non-syncytium inducing (NSI)
variants to the more cytopathic CXCR4 (X4), syncytium
inducing (SI) variants [41]. The emergence of X4 variants
during an infection is associated with an accelerated pro-
gression towards AIDS [43]. After the development of
Highly Active Anti-Retroviral Therapy (HAART), it
became clear that HIV-1 infection was a highly dynamic
process involving massive covert replication of HIV-1 in
lymphoid tissues at all stages of an infection with contin-
ual destruction and regeneration of CD4+ lymphocytes
[50]. It is estimated that HIV-infected cells and plasma vir-
ions have drastically shortened average life spans in vivo
– 2.2 and 0.3 days respectively [14-16,51]. Uninfected T
lymphocytes can survive >80 days by comparison [51]. If
the estimates of total HIV virion production of 10.3 × 109
virions a day are correct, then statistically there are enough
virions present in an in vivo infection to cause massive
direct CPE [52,53].
In vitro, HIV causes two types of CPE – syncytia and single
cell lysis. Syncytia are formed when Env expressed on an
infected cell late in infection interacts with CD4 of a
neighboring cell, triggering the fusion peptide of TM to
fuse the two membranes. Repeated occurrences of this
event allows for the formation of giant, multinucleated
cells. This type of CPE is thought rarely, if ever to occur in
vivo, and in fact rarely occurs during infection of human
PBL's in vitro, with the possible notable exception of the
brain [54-56]. HIV patients with AIDS Dementia Complex
(ADC) are found to have many giant, multinucleated cells
in the brain upon autopsy, mostly consisting of glial cells
known to express CD4. In addition to multinucleated syn-
cytial cells, single cells infected with HIV undergo a proc-
ess termed balloon degeneration whereby cells swell up
beyond the limits of their membrane integrity and lyse.
This is by far the most common type of CPE observed in
vitro [10,20,36,57]. Cell swelling in this case appears to be
irreversible in most cells, though it has been hypothesized
that those cells which can overcome these alterations in
cell volume may survive to become a population of chron-
ically infected cells [20]. One factor that both of these
types of CPE have in common is increases in cell volume.
Though syncytia do not generally lyse, they do show
increases in cell volume.
Experimenting with Sendai virus, Micklem and Pasternak,
1977 observed that alterations in the plasma membrane
of infected cells occurred within minutes of adsorption of
the virus [58]. These alterations included: changes in
intracellular ion concentrations, osmotically driven water
entry, and an increase in cell volume [59,60]. Basford et
al., 1984 hypothesized that after direct fusion of Sendai
virus lipid membrane with the host cell, the viral lipids
and proteins introduced into the host cell were able to
perturb the membrane in a manner reminiscent of the bee
venom melittin [61]. In the case of HIV, Grewe et al., 1990
noted that early interactions of HIV with host cell mem-
branes were similar to those observed with Sendai virus
[62]. Further evidence provided by Rasheed et al., 1986
showed that HIV was able to cause CPE as an early event.
UV-irradiated HIV, lacking the ability to replicate but still
able to infect cells by direct fusion of its lipid membrane
to the host cell still caused single cell balloon degenera-
tion of the RH9 T lymphoblastoid cell line. Cloyd and
Lynn, 1991 further proved that the permeability of the
host plasma membrane was enhanced early (12–24
hours) post infection to small molecules such as Ca2+ andVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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sucrose, with greater permeability seen later (24–72
hours) post infection [54].
Viral ion channels, or viroporins, are present in many lytic
animal viruses. The cellular plasma membrane maintains
cellular materials and ionic gradients necessary for the
proper functioning of the cell. The ability to alter intracel-
lular ion concentrations is necessary for many of these
animal viruses in their life cycles and is a common theme
of cytolytic viruses [63,64].
HIV infection causes increases in intracellular monovalent
cations during infection analogous to what has been
observed for other animal cytolytic viruses, such as polio-
virus and sindbis virus. Acute infection of RH9 cells, a T-
lymphoblastoid cell line, with HIV-1HXB2, a lab adapted
strain, increases intracellular Na+ and K+ concentrations as
measured by ion sensitive dyes [65,66]. The flow of the
osmotically active monovalent cations, K+ and Na+ into
infected cells correlates with CPE. Increased intracellular
ion content is expected to be associated with increased
water influx into the cell to balance osmolarity, thereby
expanding the total volume of both single and syncytial
cells. Furthermore, strains of HIV known to be more cyto-
pathic, the syncytium inducing (SI) strains, induced
greater increases in [Na+]i and [K+]i than did non-syncy-
tium inducing (NSI) strains of HIV [66]. This correlation
remained when primary isolates of HIV were used in place
of the lab adapted strain, and when primary human
PBMC's were used in place of immortalized RH9 cells
[66].
Addition of loop diuretics such as bumetanide and furo-
samide, specific inhibitors of the Na+/K+/2Cl- cotrans-
porter, at least partially blocked increases in [Na+]i and
[K+]i levels, suggesting that HIV alters this transporter's
normal function in cell volume control [67]. Makutonina
et al., 1996 observed a concomitant decrease in pH, from
pH 7.2 in uninfected cells, to pH 6.7 in HIV-infected RH9
cells using a pH sensitive dye [68]. Use of the Na+/H+ ant-
iporter inhibitor amiloride did not further decrease HIV
infected cell pHi, but did decrease control cells. This
implies that HIV may be inhibiting the Na+/H+ antiporter
in some manner. The authors further suggest that the
increases in [Na+]i observed during infection may itself
lead to this shutoff as it would be unfavorable to exchange
an extracellular Na+ for an intracellular H+ when the [Na+]i
is already high.
Some viruses alter intracellular ion concentrations in
order to get their mRNA's preferentially translated. Cellu-
lar mRNA's are only functional within a narrow range of
intracellular ion concentrations, while viral RNA's have
been shown to be more resistant [69-73]. Previous studies
involving animal cytolytic viruses have shown that alter-
ing the external ion concentration can affect internal ion
concentrations and pathogenesis of the virus. Altering the
external concentration of K+  in the medium of HIV-
infected RH9 cells alters the cytopathicity of HIV [65].
Decreasing [K+]e to zero abrogates visible CPE in cell cul-
ture and lowers HIV protein translation by 40–50%. Alter-
natively, increasing [K+]e from 5 mM (normal) up to as
much as 75 mM increases visible CPE and increases HIV
protein translation as much as three fold. Altering [K+]e
with primary human PBMC's has an even greater effect on
CPE and protein translation than it had with cell culture.
Alteration of the external Na+ concentration did not affect
CPE or HIV protein translation [65]. For comparison,
increased [K+]e does not increase poliovirus or Sindbis
virus production or CPE [69,70].
Selected Literature review of viral membrane permeability 
altering proteins
Increased membrane permeability caused by viroporins,
glycoproteins, and proteases is a typical feature of animal
virus infections [63]. Viroporins are virally encoded, small
(generally ≤120 amino acid residues) membrane proteins
that form selective channels in lipid membranes. These
channels are less discriminating than the highly selective
ion channels of bacteria and eukarya and have been
hypothesized to be a family of primordial proteins which
predate the latter [27]. Features common to viroporins
include: promoting the release of virus, altering cellular
vesicular and glycoprotein trafficking, and increasing
membrane permeability. Amphipathic α-helical domains
of viroporins generally oligomerize to form the channel
by inserting into lipid membranes with the hydrophobic
residues oriented towards the lipid bilayer and the
hydrophilic residues facing in towards the lumen of the
channel. Though viroporins are not essential for virus rep-
lication, they may be necessary for full pathogenesis in
vivo as they are known to enhance virion production and
release [64,74,75]. Many lytic viruses employ altered
[ion]i (intracellular ion concentrations) in various stages
of their replication cycles. This can include steps such as
uncoating, host cell translation shutoff, and release of vir-
ions from infected cells. Viroporins are not the only strat-
egy viruses employ to alter [ion]i – other strategies include
generalized membrane destabilization and alteration of
existing ion channel and pump functions or expression
[20,63,64].
Influenza virus
The prototype viroporin, M2 protein, was first isolated
from the influenza A virus. M2 protein is one of three pro-
teins found in the virion envelope and is present in less
abundance than either of the other two envelope proteins,
hemagglutinin (HA) and neuraminidase (N) [76]. Early
studies to block influenza A virus infection showed that
the virus was sensitive to the compound amantadine atVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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two stages of its replication cycle [77,78]. The first block
occurs early in infection after attachment, but before
uncoating. As a consequence of this block, a buildup of
nondissociated matrix (M1) and ribonucleoprotein
(RNP) occurs in endosomal compartments [79,80]. The
second block occurs late in infection and inhibits the
release of virions [81]. At this late stage of infection,
amandatine causes a buildup of HA protein during trans-
port through the trans Golgi network that has undergone
the acid-induced conformational changes normally
observed with viral entry.
Sequencing of viruses with amantadine resistance
mapped the mutations responsible for resistance to the
transmembrane domain of the M2 protein, a highly con-
served protein, even across human, swine, equine, and
avian strains of influenza A virus [78,82]. The transmem-
brane domain of the M2 protein models to form amphip-
athic α-helices that associate minimally as homotetramers
in membranes, forming an ion channel [81,83]. Expres-
sion of M2 RNA in Xenopus oocytes and analysis of whole
cell currents showed a channel selective for monovalent
cations that was activated by low pH [84], though later
experiments showed the channel to be ~1.5 – 2.0 × 106
more selective for H+ than Na+ [85]. Mutations in the
membrane spanning domain of M2 that conferred aman-
tadine resistance also decreased the conductance of these
variant M2 proteins when expressed in Xenopus oocytes.
Purified M2 protein, as well as peptides corresponding to
the TM region of M2, produced an increased conductance
of planar lipid bilayers at low pH that was able to be
blocked by the addition of amantadine [86,87]. It was
then theorized that the M2 protein acts after receptor
mediated endocytosis to acidify the interior of the virion
and dissociate the matrix protein from the ribonucleopro-
tein (the first block seen with amantadine), allowing the
ribonucleoprotein (RNP) to enter the cytoplasm. The M2
protein was also theorized to work late in infection to pre-
vent Golgi vesicle acidification. This prohibits a prema-
ture change in conformation of the HA protein (the
second block seen with amantadine), which would halt
the assembly of virions. It is important to note that viruses
deficient in M2, while severely delayed in growth kinetics
are able to undergo multiple rounds of replication in cul-
tured cells. Thus the M2 protein is not essential for influ-
enza A virus replication, but does enhance viral
productivity [64,82,88].
A protein analogous to the M2 protein of influenza A virus
was discovered in the influenza B virus genome. The NB
protein (a.k.a. – BM2) shares many characteristics with
the M2 protein. Peptides corresponding to the predicted
transmembrane region form α-helices and increase the
conductance of lipid bilayers [89,90]. This conductance is
inhibited by amantadine, though at a higher concentra-
tion than is necessary for the M2 protein of influenza A
virus [91]. Purified whole NB protein also increases the
conductance of lipid bilayers in a fashion similar to the
TM region peptides [92]. NB protein expressed in either
Xenopus oocytes or mammalian cells form a proton selec-
tive channel that is presumably used in a manner analo-
gous to the M2 protein of influenza A virus; for
acidification of the virion during uncoating in the endo-
somal compartment and to equilibrate Golgi vesicles to
prohibit premature acid-induced conformational changes
in the HA protein of influenza B virus [93]. Single amino
acid mutations in the transmembrane region of the NB
protein abrogate proton selectivity of the channel, further
supporting an analogous role for NB in influenza B virus
infections [94].
Early evidence suggests that influenza C virus also encodes
an ion channel (CM2) that is a minor virion component
[95]. CM2 protein has been shown to possess an α-helical
transmembrane domain similar to both the M2 and NB
proteins discussed above [96]. However, expression of
CM2 protein in Xenopus  oocytes shows a voltage-acti-
vated, Cl--selective ion channel that was not activated by
low pH, nor was it inhibited by even high (1 mM) concen-
trations of amantadine [97]. Studies involving influenza
C virus uncoating do not show a dependence on low pH
to dissociate the matrix and ribonucleoproteins. At the
present time it remains unclear how CM2 protein func-
tions during influenza C virus infection.
HIV
Viral protein U (Vpu) of HIV-1 (and SIVcpz) is an integral
membrane protein found predominantly in the endoplas-
mic reticulum (ER) and Golgi. It is possibly found to a
lesser extent the plasma membrane, but does not seem to
be present in the virion [98,99]. Vpu is expressed late in
infection as a bicistronic RNA that also codes for the Env
protein, which is differentially spliced to produce each
protein (see Figure 3). HIV-1 virions deficient in Vpu are
impaired in their ability for correct assembly and release.
A large proportion of these mutant virus particles display-
ing altered size and shape from wild type virions remain
attached to the cell surface [75]. Vpu possesses two func-
tional domains known to enhance the release of virions
from infected cells. The C-terminal cytoplasmic tail of Vpu
functions to enhance the degradation of CD4 in the ER
[100]. Vpu does not accomplish this task directly, but
instead binds CD4 and β-transducin repeats-containing
protein (β-TrCP), forming a ternary complex. Formation
of this complex requires two phosphorylated serine resi-
dues (52 and 56) of the Vpu cytoplasmic tail and targets
CD4 for proteolysis using the ubiquitin-dependent prote-
osome pathway [27,101,102]. It is thought that decreas-
ing the level of expression of CD4 decreases the formation
of CD4:Env complexes in the ER, allowing for increasedVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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levels of Env expression on the plasma membrane.
Increased levels of Env expression at the plasma mem-
brane in turn increases the frequency of virion budding.
The N-terminus of Vpu contains a string of hydrophobic
amino acid residues that are predicted to form an α-heli-
cal secondary structure and span the ER membrane [90].
This predicted structure is supported by experimental evi-
dence employing solution and solid-state NMR spectros-
copy, as well as CD spectroscopy [102-104]. The presence
of a functional transmembrane domain of Vpu is corre-
lated with an enhanced rate of release of virus [105].
When Vpu is expressed in E. coli, Xenopus  oocytes, or
incorporated into lipid bilayers an increased conductance
across each of these membranes is observed
[102,105,106]. Analyses of conductances observed in the
presence of altered extracellular cation concentrations in
these studies suggest that Vpu is selective for monovalent
cations. Expression of Vpu with a scrambled transmem-
brane sequence ablated the increased membrane conduct-
ance of lipid bilayers and Xenopus oocytes [105]. Just how
altering the intracellular ion concentration ([ion]i) of the
ER and/or Golgi enhances the release of virus particles is
still unclear. It has been hypothesized that a collapse of
the membrane potential at various points (ER, mitochon-
drial, and/or plasma membranes) could help to promote
virion fusion and release [27], though how this works
mechanistically has yet to be worked out.
Incorporation of only the transmembrane domain of Vpu
was sufficient to increase planar lipid membrane conduct-
ance, whereas expression of the C-terminal intracellular
domain did not [102,105]. However, addition of the two
amphipathic α-helices just C-terminal to the transmem-
brane domain, and surrounding the two serine residues
necessary for the CD4 degradation function of Vpu seems
to promote the oligomerization of Vpu in membranes as
well as stabilize the conductive state of the channel [102].
Vpu oligomerizes minimally as a four-helix bundle, but
most likely as a five helix bundle [107,108]. Tryptophan
residues at position 22 are thought to situate their head-
groups into the lumen of the channel, creating a narrow
constriction or gate in the closed form of the channel.
Rotation of the hydrophobic tryptophan residues around
the helical axis is thought to create a more open structure
and expose polar serine residues at position 23 in the
open state of the channel, allowing monovalent cations to
selectively flow through the channel.
Alternatively, Vpu could be interacting with an endog-
enous ion channel to alter its normal function and modify
membrane conductance. Coady et al., 1998 report that
expression of Vpu in Xenopus oocytes decreases membrane
conductance by decreasing expression of an unidentified
endogenous membrane channel via degradation in the ER
[109]. Furthermore, these authors purport that the
increased membrane conductance observed in previous
studies was an artifact of the injection of large amounts of
RNA and that randomization of the TM sequence also
served to ablate its ability to interact with the endogenous
ion channel. Expression of exogenous proteins in Xenopus
oocytes has been shown to sometimes induce non-spe-
cific conductances [110]. In support of this theory, Hsu et
al., 2004 show that Vpu can physically interact with and
inhibit TASK-1, an endogenous mammalian K+ channel
[111]. Though the results using planar lipid bilayers in the
absence of all proteins except Vpu argues against the con-
clusion that Vpu conductance is solely caused by interac-
tion with endogenous channels, it does not eliminate this
possibility as Vpu's primary mode of action or that Vpu
may employ both modes of action.
Sindbis virus
Sindbis virus, a member of the family Togaviridae is an
enveloped and positive sense RNA cytolytic virus of ani-
mals. Sindbis virus is known to increase and decrease the
intracellular concentration of Na+  and K+  respectively
[112,113]. Late in Sindbis virus infection there is a mas-
sive shut-off of host protein translation. An increase in
[Na+]i correlates with the shutoff of host protein synthesis,
though Sindbis virus protein synthesis continues and
appears to favor these intracellular ionic conditions to
force its proteins to be preferentially expressed over host
cell proteins.
The cause of the observed increase in membrane permea-
bility appears to be an accessory protein named 6K pro-
tein. 6K protein has many similarities to Vpu of HIV-1 –
they are small (~60 amino acid residues) hydrophobic, α-
helical proteins that associate with membranes [114].
Viruses deficient in 6K protein are replication competent,
but are deficient in virion budding [74,115]. 6K protein is
produced in the ER and is post-translationally cleaved
from the virion glycoproteins E1 and E2. All three pro-
teins are then transported via the Golgi to the cell surface,
but 6K protein is not incorporated into virions. 6K-defi-
cient sindbis virus mutants are at least partly restored by
the expression of Vpu in trans [116].
6K protein increases membrane permeability to the trans-
lation inhibitor Hygromycin B in eukaryotic cells [115].
Inducibly expressed in E. coli, 6K protein induces leakage
in the bacterial cell membrane and cell death [117]. Incor-
porated into planar lipid bilayers, 6K proteins (produced
in E. coli or synthetically derived) increase membrane
conductance and form cation selective ion channels that
are reversibly inhibited by polyclonal antibodies [118].Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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Wengler et al., 2003 reported the identification of another
possible pore that Sindbis virus uses during uncoating
that resides in the virion [119]. Sindbis virus enters the
cell by way of binding to a cellular receptor to induce
uptake into endosomal compartments [63]. Upon acidifi-
cation of these compartments, the E1 glycoprotein under-
goes conformational changes that allow for the formation
of a proposed "fusion pore". This pore is of sufficient size
to allow the capsid to enter the cytoplasm to begin
uncoating, a process that is facilitated in Sindbis virus by
a more acidic pH during interaction of the core with the
60S ribosome [120,121]. Therefore it is proposed that the
already formed fusion pore also allows H+ ions to exit the
endosome, creating a localized area of lower pH that facil-
itates disassembly of the core while not creating globally
acidic conditions in the cytoplasm that would destabilize
capsids assembled late in the viral life cycle for budding of
progeny virus [119].
In support of this idea, Nieva et al., 2004 recently reported
the identification of a membrane permeabilizing region
of E1 protein of Simliki Forest virus (a related alphavirus)
capable of permeabilizing E. coli as efficiently as 6K pro-
tein [122]. The authors suggest that this E1 domain may
additionally act as a backup membrane permeabilizing
protein to allow budding at the cell surface.
Hepatitis C virus
Hepatitis C virus (HCV), a hepacivirus of the family Flavi-
viridae, encodes a 63 amino acid non-structural protein,
P7, that is required for the formation of infectious parti-
cles and resembles the 6K protein of sindbis virus
[123,124]. When peptides corresponding to the P7 pro-
tein are mixed with planar lipid bilayers, ion channels of
variable conductance were detected [125,126]. These
channels were discovered to be selective for Ca2+ over Na+
and K+. Amantadine, a known inhibitor of the influenza
virus M2 ion channel, as well as hexamethylene amilo-
ride, a known inhibitor of the HIV-encoded Vpu, both
inhibited P7 in planar lipid bilayers [125,126]. In fact,
amantadine has shown some efficacy in clinical trials
when given in conjunction with the current treatment reg-
imen of IFN-α and ribavirin.
Sequence analysis shows that P7 contains two domains
separated by a hydrophilic stretch of amino acid residues
which are expected to span the membrane as an α-helix in
an "α-loop-α" motif [123]. Expression of P7 in HepG2
cells followed by crosslinking and analysis via Western
blot shows the formation of hexameric complexes. In
good agreement, transmission electron microscopy of
negatively stained E. coli expressing P7 shows ring struc-
tures with a diameter consistent with a hexameric arrange-
ment of proteins [126].
Though it has been observed as being present in small
amounts in the plasma membrane, P7 protein is mostly
localized to the ER, where it presumably would function
to release intracellular calcium stores. P7 from bovine
viral diarrheal virus (BVDV; a related pestivirus) is known
to facilitate virion release from the plasma membrane.
BVDV lacking P7 still replicates, but does not produce
infectious virions [124]. When P7 protein is added back in
trans, infectious virions are detected. It has been suggested
that P7 from HCV may serve a similar function, though
the mechanism of the release of calcium from intracellular
stores is as of yet unclear. These studies are complicated to
perform directly in HCV due to the inherent difficulty of
culturing HCV in vitro.
Poliovirus
Poliovirus, a non-enveloped virus and a member of the
family of Picornaviridae alters intracellular monovalent
ion concentrations during infection. An increased total
cell volume correlating with increased [Na+]i  and
decreased [K+]i is detected after a couple hours post infec-
tion with poliovirus, and has the effect of decreasing the
overall rate of protein synthesis of infected cells
[112,113,120]. Mammalian cells are known to be sensi-
tive to changes in intracellular monovalent ion concentra-
tions during translation of cellular mRNA [69,127].
Certain viral mRNA, including poliovirus mRNA, has
been shown to be less sensitive to altered intracellular cat-
ion concentrations. This presents a mechanism by which
viruses coax the host cell to preferentially translate viral
RNA over most cellular RNA. A decrease in the [NaCl] or
an increase in the [KCl] in the medium of infected cells is
able to compensate for the induced alterations of intracel-
lular monovalent cation concentrations and allow
infected cells to resume normal protein synthesis [128].
The first evidence for a particular poliovirus protein
responsible for altering intracellular ion concentrations
came from the study of a replication competent poliovirus
possessing a mutation in its 2A protease [128]. Expression
of individual poliovirus proteins using vaccinia virus in
HeLa cells identified the 2B protein (just downstream of
the 2A protein) as being responsible for actually increas-
ing membrane permeability [129]. Expression of 2B and
2BC (a precursor protein that stably exists in poliovirus
infected cells, some of which is cleaved to produce 2B and
2C), but not any other poliovirus proteins increased HeLa
cell permeability to hygromycin B. Mutations in the 2C
region of 2BC did not seem to affect its ability to increase
plasma membrane permeability suggesting that the 2B
region is primarily responsible for this task.
Analysis of the overall hydrophobic 100 amino acid resi-
dues present in the sequence of 2B reveals that it contains
two predicted α-helical regions separated by a stretch ofVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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hydrophilic amino acids [130]. Most of the N-terminal α-
helix is amphipathic, while the C-terminal α-helix con-
tains hydrophobic residues are expected to form a trans-
membrane domain. 2B induces leakage of large
unilamellar vesicles (LUV's) composed of phosphatidyli-
nositol in an ANTS/DPX assay [130]. Mutation of various
positively charged amino acids in the amphipathic α-helix
domain known to decrease membrane permeability to
hygromycin B during infection decrease the amount of
observed leakage in ANTS/DPX assays. 2B pores allow free
diffusion of compounds up to approximately 1000 Da
into or out of LUV's. Fluorescence resonance energy trans-
fer (FRET) microscopy shows multimerization in the pres-
ence of phosphatidylinositol. Western blot analysis
showed these multimers to be SDS-resistant tetramers.
Yeast 2-hybrid assays, GST pulldown assays, and FRET
microscopy in single living cells have all been in agree-
ment that 2B oligomerizes to form a pore [131-133].
Nieva et al., 2003 modeled the 2B protein to oligomerize
in such as way as to form a "barrel-stave"-like pore, where
the four amphipathic domains have the hydrophilic resi-
dues facing the lumen of the pore and the transmembrane
domains surrounding these domains to form a transmem-
brane anchor.
There have been conflicting reports on the intracellular
location of 2B – it has been reported to reside in the ER
and Golgi, as well as the plasma membrane [64,134-138].
Concurrent with increased monovalent ion concentration
during poliovirus infection, there is a profound rearrange-
ment of the ER and Golgi to the point where the Golgi
becomes unrecognizable and numerous membrane vesi-
cles fill most of the cytoplasm late in infection. Whether
the 2B protein resides in the plasma membrane to indi-
rectly affect the ER and Golgi, or resides in the ER and
Golgi having an indirect affect on the plasma membrane,
or is present in all three to produce its effects is unclear.
More research needs to be done in this area to distinguish
between these three possibilities.
It has been speculated that the capsid of poliovirus is able
to form a pore through which the virus is able to enter
cells for infection. 160S particles (intact infectious polio-
virus) possess a capsid comprised of four proteins – VP1–
VP4. VP1–VP3 make up the outer shell of the icosohe-
drally shaped capsid with their N-termini situated on the
inner surface where the entire VP4 protein resides
[139,140]. After poliovirus interacts with the Poliovirus
Receptor (PVR), there is a rearrangement of capsid pro-
teins such that the N-terminus of VP1 relocates to the
outer surface and VP4 is lost from the virion, creating
135S particles. The N-terminus of VP1, which models to
form amphipathic α-helices, and VP4, which localizes to
the cellular membrane after attachment primarily through
a myristolated amino acid residue, are then thought to
form a pore or ion channel. Increased conductances across
model lipid membranes after addition of 135S particles
were measured by Tosteson et al., 1997 and proved to be
consistent with this hypothesis [140-142].
Rotavirus
Rotavirus (RV) encodes two suspected ion pores that act
in different stages of its replication cycle. RV infects the
gastrointestinal tract and is a significant cause of diarrheal
disease in infants, but does not cause diarrhea in infected
adults. A single protein, nonstructural protein 4 (NSP4)
has been identified as causing diarrhea and was the first
virally encoded enterotoxin identified [143-145]. A pep-
tide corresponding to NSP4 amino acid residues 114–135
is also capable of evoking diarrhea in mice, albeit to a
lesser extent than the full protein. Circular dichroism
shows this peptide to form α-helices and partition into
model lipid membranes and is thought to be the lipid
binding domain of NSP4 [146]. Addition of NSP4 protein
to gastrointestinal epithelial cells evokes intracellular cal-
cium mobilization most likely from the endoplasmic
reticulum (ER). This in turn triggers halide movement
across the plasma membrane in what is thought to be the
age-dependent step. Finally, transepithelial movement of
Cl-, followed by Na+ and water into the lumen occur
[145]. This secretory diarrhea occurs independent of cyclic
nucleotides and the CFTR and in the absence of inflam-
mation. The crystal structure for NSP4 has been solved
and predicts that NSP4 could form a homotetrameric pore
to potentially span the ER and act as a calcium channel
[147]. While this theory has yet to be directly tested, there
are a couple facts which suggest this possibility: 1) the pre-
dicted hydrophobic interior of the NSP4 pore contains a
calcium-binding domain and 2) NSP4 does not alter
plasma membrane calcium permeability, but does alter
calcium release when expressed within cells.
Rotavirus is nonenveloped and is thought to enter cells
through direct penetration. VP4, a structural protein
present on the surface of the virion, is cleaved into VP5
and VP8 after treatment with trypsin or after uptake into
early endocytic vesicles. Golantsova et al., 2004 report
that VP5 has two discrete domains used to penetrate into
the cytoplasm. The first domain directs peripheral mem-
brane association, while the second permeabilizes, but
does not lyse membranes [148]. VP5 is thought to form
transient and size-selective lipidic pores ("ion flicker
pores") which allow small molecules to pass. The pres-
ence of this pore in an early endocytic vesicle containing a
rotavirus virion could allow the [Ca2+] in the vesicle to
drop – the first step needed for uncoating of the virion and
eventual penetration of the virion into the cytoplasm of
the cell.Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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Existing evidence that the LLP domains of TM HIV may 
constitute a viroporin
Though it is thought that HIV contains at least one virop-
orin in Vpu, there is evidence that it codes for more than
one. First, Vpu is not present in virions, but membrane
perturbations leading to increased intracellular ion con-
centrations may be an early event in HIV infection
[36,54]. Addition of UV-inactivated virus to RH9 T-lym-
phoblastoid cells, which can attach to and enter cells, but
cannot replicate, causes syncytium formation and single
cell balloon degeneration. These cytopathic effects – syn-
cytial cell formation, balloon degeneration and cell death
– are all observed in the absence of reverse transcription
and provirus formation [36].
Ultrastructural analysis of RH9 cells infected with intact
HIV virions illustrates partial separation of lipid bilayers,
formation of distinct "pores", perturbations, or mem-
brane thickenings within one hour of exposure [149].
Concurrent with these plasma membrane observations
were observations of extensive cytoplasmic vacuolization
of the endoplasmic reticulum (ER). Vacuolization was
most prominent in cells with the highest numbers of
bound virions. The authors hypothesize that the cell may
be pumping excess ions into the ER, which is followed by
water to osmotically balance the ER lumen. This could
direct the maintenance of total cell volume in the early
stages of infection after disruption of the plasma mem-
brane and resulting ion influxes. Both of these studies
indicate the involvement of an actual virion component
in CPE.
Analysis of the Env protein, the major protein present in
the virion envelope, led to the discovery of 2 domains in
the extreme C-terminus of the long (~150 amino acid)
cytoplasmic tail of TM that have a high hydrophobic
moment [150]. These domains were identified on the
basis of their structural motifs and similarities to several
natural cytolytic peptides, such as magainin-2 and were
given the names LLP-1 and LLP-2 [150,151]. A third
domain located between the first two, LLP-3, was discov-
ered later [152]. Magainins are hemolytic, but at concen-
trations 1–3 orders of magnitude higher than is needed
for bactericidal activity [153]. Analysis using the patch
clamp technique identified magainin-2 as a voltage-
dependent ion channel [154]. Biochemical analyses
yielded insights into the mechanism of action of
magainin-2. This peptide is cationic, amphipathic, and
adopts an α-helical secondary structure in the presence of
lipid [153,155]. Molecular modeling studies supported by
experimental evidence suggested that the activity of
magainin-2 is tied to its ability to form a multimeric struc-
ture after insertion into lipid membranes [156,157]. Sim-
ilar structure-function relationships have been discovered
for other natural lytic peptides, such as the cecropins of
the North American silk moth, Hyalophora cecropia, and
melittin from the venom of the honey bee, Apis mellifera
[157,158].
Figure 5A contains helical wheel diagrams of each LLP
domain from the HXB2 strain of HIV-1, as well as their
primary amino acid sequence (Figure 5B). When plotted
as  α-helices, it is apparent that all three domains are
amphipathic, generally with hydrophilic residues
(colored blue) clustered on one face of the α-helix and
hydrophobic residues (colored red) clustered on the
opposite face. LLP-3 differs from LLP-1 and -2 in that it
lacks the positively charged residues on its hydrophilic
face. This secondary structure is conserved across HIV-1
clades, though primary amino acid identity is not [151].
As discussed in Figure 5, helical wheel diagrams suggest
these regions have a high propensity to form amphipathic
α-helices [150]. Not only are the structure of these LLP-1
and -2 domains highly conserved across all strains of HIV-
1, they are conserved across other lytic lentiviruses such as
HIV-2, SIV, and equine infectious anemia virus (EIAV) as
well, though primary amino acid sequence does vary and
as such is not conserved [151]. Closely related nonlytic
oncoviruses, including murine leukemia virus lack these
conserved amphipathic α-helical structural motifs,
though they contain similarly long cytoplasmic tails. The
structure of LLP-1 and -2 domains resemble proteins of
ion-selective channels, such as the S4 domain of K+ chan-
nels, as do the natural cytolytic peptides of the honey bee
(melittin) and amphibians (magainins)
The LLP domains Figure 5
The LLP domains. (A) Helical wheel diagrams showing the 
amphipathic nature of each LLP domain. The coloring scheme 
is from Benner et al. and graphs were generated using a java 
applet available at the PredictProtein server [221]. (B) Pri-
mary amino acid sequence of LLP peptides which correspond 
to the LLP-1, -2, and -3 domains of the TM protein are given 
from the helical wheels in (A).Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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[150,151,158,159]. Based on analogy to other lytic pep-
tides with similar secondary structure such as magainin-2,
and on the observation that when in an anti-parallel
arrangement, LLP-1 and -2 exhibit charge complementa-
rity, it has been hypothesized that LLP-1 and LLP-2 could
aggregate in lipid membranes with their charged (mostly
arginine) residues facing towards each other and their
hydrophobic residues facing out toward the lipid bilayer
to form an ion channel or a pore [160]. A third domain
dubbed LLP-3, located between the LLP-1 and -2 domains
shows a propensity to form an amphipathic α-helix, but
lacks the charged residues on one face, instead possessing
a leucine zipper-like sequence [152]. LLP-3 could, in the
context of the full protein, span the lipid bilayer to help
form the channel. It is also possible that LLP-3 could inter-
act with LLP-1 and 2 in a manner that aids in their aggre-
gation, an assertion the Kliger et al., 1997 based solely on
analogy to other leucine zipper-containing proteins.
Studies utilizing synthetic peptides of identical amino
acid sequence to the LLP-1 domain have supported the
hypothesis that LLP-1 can oligomerize, insert into mem-
branes and form pores. LLP-1 peptides of HIV-1 and SIV
were bactericidal to both gram(-) and gram(+) bacteria at
micromolar concentrations within a few minutes
[151,161-163]. These peptides were also capable of lysing
red blood cells (RBC's) and RH9 T-lymphoblastoid cells
in similar concentration ranges. LLP-1 peptides were more
effective than the natural amphibian cytolytic magainin
peptides in these assays. Mutation of 2 – 3 of 7 positively
charged arginine residues present in LLP-1 to neutral
glutamate residues resulted in an almost complete loss of
activity against both prokaryotic and eukaryotic cells in
lysis assays [151,161]. Glutamate was chosen to preserve
the overall hydrophobic moment of LLP-1 as well as to
preserve its secondary structure. Thus, the overall positive
charge provided by its arginine residues is most likely nec-
essary for its function.
Experimental evidence supports the theoretical models of
the LLP domains' secondary structure and function. Circu-
lar dichroism studies show that synthetic peptides corre-
sponding to these regions have little secondary structure
in water, but adopt an α-helical secondary structure in the
presence of a lipid environment [152,162,164-166].
Transmission electron microscopy studies confirm that,
similar to data gathered using magainin-2, LLP-1 interacts
with both the inner and outer leaflets of the cytoplasmic
membrane of the bacteria Serratia marcescens [167]. Bacte-
ria exposed to LLP-1 displayed a decreased cytoplasmic
density from negative controls indicating that the mem-
brane had been compromised. Furthermore, addition of
membrane impermeable ONPG to LLP-1-incubated, but
not control cultures, led to its hydrolysis over time, indi-
cating that it was able to gain access to the β-galactosidase
enzyme located in the cytoplasm of bacteria [162]. Both
LLP-1 and LLP-2 were able to cause time- and dosage-
dependent release carboxyfluorescein entrapped egg PC
vesicles at micromolar concentrations. When added to
LUV's of various lipid compositions, 15-mer peptides
spanning all three LLP regions were capable of causing
leakage, phospholipid mixing, and fusion to differing
extents [168]. The presence and amount of sphengomye-
lin as well as cholesterol correlated positively with these
peptides' functions in these assays, though similar trends
were observed between strains of HIV.
In a subsequent attempt to define the size of the pore cre-
ated by LLP-1, Miller et al., 1993 measured the amounts
of 45Ca, 14C-sucrose, and 14C-inulin that were able to enter
LLP-1 treated CEM cell cultures [169]. 45Ca (M.W. = 45
Da) and 14C-sucrose (M.W. = 342.3 Da), but not 14C-inu-
lin (M.W. ~5000 Da) were able to pass through LLP-1
treated membranes, suggesting that LLP-1 could form a
pore of a definable size and did not simply destabilize or
disintegrate the membrane. In good agreement, mem-
brane perturbation studies utilizing whole virus show that
hygromycin b (MW 527) was able to enter cells after infec-
tion with HIV-1, while G418 (MW 693) was not able to
enter [170]. This suggests that the pore created by the LLP
domains has a cutoff between MW 527 and 693.
Topological analysis of full length TM of HIV-1 using
sequence specific antibodies showed that not only did TM
contain an N-terminal transmembrane anchoring
domain, but it also formed secondary associations at the
C-terminal end which blocked antibody binding [171].
Furthermore, the association of the cytoplasmic tail with
microsomal membranes made from canine pancreas con-
ferred resistance to extraction via carbonate treatment,
suggesting that the association observed earlier was not
merely an artifact of having a conformational dependent
antibody. The association of the cytoplasmic tail with
lipid membranes was also resistant to high salt extraction
and proteolysis [172]. Expression of just the cytoplasmic
tail of TM associated with lipid membranes and was suffi-
cient to get cell surface expression of the tail fragment
[173]. Sucrose gradient centrifugation, chemical cross-
linking, and gel filtration analysis of an MBP-cytoplasmic
tail fusion protein proved the formation of a higher
ordered, multimerized structure, dominantly a hexamer.
Analysis of the same fusion protein in a mammalian 2-
hybrid assay and in a GST pull-down assay complemented
these studies in eukaryotic cells [174]. In fact, the authors
concluded that the cytoplasmic tail itself is sufficient to
oliogomerize Env.
LLP-1 causes increased the conductance of various mem-
branes when added exogenously. LLP-1 bound preferen-
tially to planar lipid bilayers composed of negativelyVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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charged phosphatidylserine (PS) over neutral diphytanoyl
phosphatidylcholine (DPC) bilayers and as such, all
experiments were performed using PS bilayers [175]. At
micromolar concentrations there was an overall increased
conductance at negative and positive voltages. A prefer-
ence for cations over anions was observed, with no prefer-
ence of Na+ or K+. The effect of exogenous LLP-1 peptides
on whole-cell conductance of (Sf9) insect cells was meas-
ured in the same study. Nanomolar LLP-1 concentrations
increased mean membrane conductance at positive and
negative voltages by approximately 10 fold using the
patch clamp technique. Nanomolar concentrations of
exogenous LLP-1 were also able to increase the whole cell
conductance of Xenopus laevis oocytes [176]. Much
Smaller conductances were induced by equal concentra-
tions of the lytic peptide melittin. Up to four times the
concentration of HIV-1 Nef accessory protein did not
increase oocyte membrane conductance over control,
untreated oocytes.
Ultrastructural analysis of eukaryotic cells incubated with
LLP-1 peptides uncovered features of necrosis as the main
cause of death of these cells [177]. The most striking fea-
tures visible under electron microscopy are extensive vac-
uolization of the endoplasmic reticulum and
mitochondria. The authors attribute this to a concentra-
tion of ions and water into these cell organelles attempt-
ing to compensate for increased intracellular levels of ions
and water caused by LLP-1 peptides. Plymale et al., 1996
also observed a small increase in the levels of apoptosis in
these cells [178]. The increase in the numbers of cells
undergoing apoptosis under these conditions was very
small compared to the increase in cells undergoing necro-
sis. The magnitude of the increases was influenced by the
cell type and the concentration of LLP-1. Lower "sub-lytic"
concentrations of LLP-1 tended to cause more apoptosis
than higher "lytic" LLP-1 concentrations. Thus apoptosis,
like syncytia formation, appears to be a mechanism which
HIV can utilize to cause cytopathology, but is not likely
the dominant mechanism utilized in vivo.
By virtue of its amphipathic α-helical secondary structure,
LLP-1 has homology to calmodulin binding proteins and
has been proposed as a mechanism behind HIV's ability
to cause apoptosis in cell culture. HIV virions which pos-
sess full-length TM cytoplasmic tails, but not virions with
truncated tails lacking LLP domains, are able to bind cal-
modulin [179]. Peptides corresponding to both the LLP-1
and -2 domains bind calmodulin with high affinity, irre-
spective of natural sequence variation present in different
clades of HIV [161,180]. When added exogenously to T
cells in vitro, both LLP-1 and -2 inhibited T cell signal
transduction through the NF-AT complex via sequestra-
tion and titration of available calmodulin (Figure 6). LLP-
1 and -2 were as effective at inhibiting calmodulin as the
known calmodulin inhibitor, W-7 [181]. The end result of
calmodulin inhibition observed in these studies was a
decrease in IL-2 production leading to T cell anergy and
increased levels of apoptosis. It has long been observed
that immune cells from HIV infected patients are less
responsive than HIV seronegative persons though it
remains to be seen whether significantly increased HIV-
induced apoptosis occurs in vivo at all [182]. However, cell
culture experiments tend to suggest that apoptosis is not a
major contributor to cell death as only marginal increases
in apoptotic cells are observed throughout the course of
HIV infected cell cultures compared to necrotic cell death
[177].
TM has been implicated in altering [ion]i thought to be
responsible for the impairment of brain function known
as AIDS Dementia Complex (ADC). Upon necropsy, neu-
rohistopathology of the CNS shows morphological
abnormalities and death of neurons, astrogliosis, micro-
glial nodules, and multi-nucleated giant cells consisting of
monocyte-macrophages and microglial cells [55]. Patients
with ADC have increased levels of glutamate+ in their CSF
[183]. Glutamate+  is an excitatory amino acid (EAA)
whose levels are closely regulated by glial cells in the brain
because excess glutamate+ in neuronal synapses is toxic.
Though neuronal infection is generally non-productive in
vitro, an increase in extracellular [EAA] is observed after
acute infection of neurons by HIV. Analysis of virion pro-
teins proved that TM was sufficient to cause the increased
[EAA]e. Addition of exogenous peptides with sequences
corresponding to the LLP-1 domain of TM had the same
Calmodulin binding activity of the LLP domains Figure 6
Calmodulin binding activity of the LLP domains. Pro-
posed action of LLP-1 and -2 binding of calmodulin in T cell 
anergy. The LLP domains are thought to disrupt the signaling 
cascade through titration of calmodulin. Figure was produced 
based on data from Beary et. al, 1998 [181].Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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effect as the expressed TM protein. It was postulated by
Kart et al., 1998 that LLP-1 had its action through ablation
of the Na+  gradient, a postulated action of the LLP
domains (discussed more in depth below)[183]. Without
the Na+  gradient to drive the Na+-glutamate+  cotrans-
porter-mediated electrogenic uptake of glutamate+ against
its large concentration gradient across the plasma mem-
brane, [EAA]e and [cation]e increase. Bubien et al., 1995
report that SU added exogenously to cultures of rat or
human astrocytes stimulates the Na+/H+  exchanger to
alkalinize the cytoplasm [184]. This in turn inhibits the
Na+-dependent uptake of glutamate+ against its concen-
tration gradient and activates pH-sensitive K+ channels to
release intracellular K+. It is thought that impairment of
the astrocytes' ability to maintain the proper [EAA]e and
[ion]e leads to improper firing of neuron potentials and
neuronal cell death. It is unknown at this time what the
relative contributions of each of these pathways may be in
vivo to developing ADC.
Previous work on TM and its ability to perturb mem-
branes focused on truncations in the context of whole vir-
ions [185-189]. These studies produced conflicting
reports of the function and necessity of the C-terminus of
TM during infection. Results gained from these trunca-
tions vary between producing no effect at all to one or
more of decreases in viral entry, infectivity, cytopathic
effect, and envelope production, processing, stability, cell
surface expression, and virion incorporation. Two points
that these studies generally agree on is that HIV virions
with truncated TM cytoplasmic tails are replication com-
petent and that most effects observed in these mutant
viruses are cell type dependent. Discrepancies between
studies likely involve the disruption of multiple domains
contained within the cytoplasmic tail of TM, depending
upon the extent of each truncation. Several studies have
indicated that there may be domain(s) in the C-terminus
of TM that interact with HIV Gag proteins to assemble vir-
ions [24,190]. In addition to interacting with Gag, it has
been hypothesized, though not proven, that the cytoplas-
mic tail of TM may interact with cellular factors, and that
this may be the source of the cell-type dependent effect
[191-193].
Studies involving site-directed mutagenesis of specific
domains within the cytoplasmic tail may help to clear up
some of the confusion caused by the truncation studies.
Kalia et al., 2003 engineered infectious virions with muta-
tions of the LLP-1 and -2 domains [194]. Three mutant
viruses were produced, one with 2 arginine to glutamate
mutations in LLP-1, another with 2 arginine to glutamate
mutations in LLP-2, and a third incorporating the same
mutations in LLP-1 and -2, but in the same virus. Syn-
thetic peptides corresponding to these domains which
include these mutations were previously found to lose
their lytic properties, as well as their calmodulin binding
activity [169,180]. The LLP-1 mutant virions displayed an
approximate 85% decrease in TM incorporation, though
Env expression and processing were unaffected. LLP-2
mutant viruses were unaffected in Env expression,
processing, oligomerization, and incorporation. Both
LLP-1 and -2 mutant viruses were decreased in their capac-
ity to cause syncytia by 70 and 90% respectively. Double
mutant viruses were similar to LLP-1 mutant viruses in
envelope expression, processing, and incorporation, but
failed to cause syncytia to the same extent as LLP-2 mutant
viruses [194].
Syncytia formation and single cell balloon degeneration
have traditionally been thought to be two distinct cyto-
pathic phenotypes caused by two distinct regions of Env –
the extracellular fusion peptide and the intracellular LLP
domains respectively. However, these two processes may
be more closely linked than previously thought. Giant,
multinucleated syncytial cells undergo increases in total
cell volume, owing to the LLP domains perturbing the
plasma membrane just as in the case of single cells. On the
other hand, Kalia et al., 2003 report that infectious clones
containing 2 each of arginine to glutamate site directed
mutations in the LLP-1 and/or LLP-2 domains exhibit a
decrease in their ability to cause cell:cell fusion [194]. It is
possible, though it remains to be proven, that the mem-
brane perturbation properties of the LLP domains could
synergize with the fusion peptide to increase the efficiency
of cell:cell fusion in a manner analogous to its function in
virion budding. Increases in cell volume due to osmotic
balancing after ion influx could disrupt the cell cytoskele-
ton allowing for greater ease of membrane fusion.
The case is more clear-cut for truncations of the cytoplas-
mic tail of the Env protein of SIV. Env truncations are doc-
umented to arise during culturing of SIV in human cell
lines [195]. Mutants revert back if cultured again in simian
cells [195,196]. While these SIV TM truncation mutants
are replication competent in vitro as well as in vivo, they
lack full pathogenicity in vivo and tend to revert back over
time [197]. Shacklett et al., 2000 showed that the cyto-
plasmic tail of SIV Env is necessary for persistence of
viremia and pathogenesis of the virus in rhesus macaques
[198]. Their group engineered 3 stop codons, a +1
frameshift mutation, and 3 arginine to glutamate site
directed mutations in the LLP-1 domain of mac239 viri-
ons, eliminating both LLP-1 and -2 regions. The resulting
mutant virions cause an initial viremia, but levels fall off
and become non-detectable over time. All viruses recov-
ered from these macaques maintained their mutations
without exception and none of the infected macaques
developed SAIDS. Juvenile macaques infected i.v. with
this mutant virus maintained low level viremia, but also
never progressed to SAIDS. 100% of macaques infectedVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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with wild type mac239 develop SAIDS over the same time
course.
LLP viroporin models and discussion
If the LLP domains form a viroporin and allow ions to
enter the cell more freely down its concentration gradient,
then water would follow in attempt to osmotically bal-
ance those ion influxes. This would represent a mecha-
nism by which HIV-1-infected cells undergo the process of
balloon degeneration.
This hypothesis allows for a mechanism by which large
versus moderate ion influxes could direct differential out-
comes for infected cells [199]. Those cells that can over-
come the osmotic imbalance may then live to become
chronically infected. Those that can't overcome this
osmotic imbalance undergo balloon degeneration. In
support of this theory, the concentration of LLP peptides
exogenously added to mammalian cell culture were previ-
ously determined to correlate with a differential outcome
on cell death [178]. The levels of apoptosis versus necrosis
of these cells – higher concentrations (>100 nM) were
shown to result in more necrosis, while lower concentra-
tions (~20 nM) resulted in more apoptosis with exoge-
nous LLP-1.
It is unknown to what extent single cell killing versus syn-
cytial cell death occurs in vivo. The central nervous system
is the only tissue where syncytial cells have been observed
in vivo at autopsy [55,200]. In the absence of observed
syncytia, it is assumed that single cell death occurs in the
rest of the body, possibly due to a lack of opportunity for
infected cells to be in close enough proximity to allow
syncytial formation. As an estimate for the amount of sin-
gle cell death that can be caused by Env in the absence of
syncytia formation, 43% of RH9 T-lymphoblastoid cells
died by single cell death after inducibly expressing Env in
the presence of soluble CD4 to prevent syncytia formation
[199].
There are three general mechanisms by which the LLP
peptides and expressed Env may act to alter oocyte mem-
brane permeability. They may be acting to modify endog-
enous ion channel function, altering its activity and
thereby increasing whole-cell conductance. This could
occur through direct contact or by shifting the intracellu-
lar ionic environment. For example, LLP-1 is known to
have the ability to bind calmodulin leading to an increase
in intracellular free calcium [161,179,180]. Calcium lev-
els have a large effect on protein activation in the cell, thus
the LLP domains could be working through this mecha-
nism exclusively, or in addition to forming a membrane
pore. Second, the LLP domains could act to nonspecifi-
cally disrupt the membrane, or specific regions of the
membrane in a detergent-like effect. Lastly, the LLP
domains may serve as viroporins i.e., insert into the mem-
brane to form pores. Mounting evidence suggests that the
last possibility is likely; however definitive differentiation
of these mechanisms would require the discovery of spe-
cific inhibitors, such as amantadine for the M2 channel of
influenza.
When partitioning into a lipid environment, LLP-1, -2,
and -3 form highly ordered α-helices that were able to dis-
rupt a variety of model lipid bilayers in the absence of all
other protein (discussed above). Consequently these
domains are capable of disrupting membranes and are
not solely dependent upon alteration of endogenous ion
channel function to alter the intracellular ionic environ-
ment. In the context of a living membrane, LLP-1 and -2
have been shown to lyse bacteria, fungus, red blood cells,
and various cultured eukaryotic cells [151,162,169,178-
180,201,202]. When added exogenously, LLP-1 can
increase the conductance of Xenopus oocytes, presumably
caused by the formation of transmembrane pores which
increase the membrane permeability of electrogenically
active ions [176]. It has thus been postulated that LLP-1,
and possibly LLP-2 peptides, oligomerize to form a "bar-
rel-stave"-like pore, which are conducting pores (barrels)
in membranes formed by the self-assembly of a variable
number of alpha-helical rods (staves). It is the formation
of these pores which then allow ions to be redistributed
across the membrane to cause osmolysis.
Recently it has been proposed that HIV, along with several
animal viruses including influenza, may utilize lipid rafts
to enter and exit cells. Lipid rafts are lipid microdomains
enriched for sphingomyelin and cholesterol that are
thought to function by aggregating proteins that require
close proximity for proper function, such as in the case of
the T cell synapse [203]. It has been proposed by several
groups that HIV-1 exploits lipid rafts during both the
entry and budding stages of its replication cycle. During
entry, lipid rafts may serve to concentrate cellular recep-
tors (CD4, CXCR4, and CCR5) for ease of entry by HIV
[204]. This could potentially be important for HIV since
entry has been shown to be dependent on the density of
receptors on the cell surface [205].
There is ample evidence that HIV-1 buds from lipid rafts
[28,206]. The composition of the HIV envelope is prima-
rily sphingolipid and cholesterol, resembling the compo-
sition of rafts. The HIV lipid envelope is furthermore
enriched for proteins known to partition into lipid rafts
and excludes proteins known to not associate with rafts
(such as CD45). HIV proteins extract with lipid raft
domains during nonionic detergent extraction at 4°C.
Lastly, the cytoplasmic tail of Env has two palmitoylated
sites known for targeting proteins to lipid rafts in a man-
ner analogous to cellular proteins' targeting to lipid raftsVirology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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[207]. One result of entry and budding through lipid rafts
is that Env proteins would be concentrated in distinct
areas on the cell surface, possibly allowing interaction of
LLP domains to form pores on the cell surface. These
pores in turn could weaken the normally stable raft area
through altered intracellular ion milieu, thereby creating
a more favorable environment for replication and bud-
ding of the virus. Hence, as infection progresses and
increasing amounts of Env are deposited on the cell sur-
face in preparation for budding, there would be a con-
comitant increase in cytopathic effects, such as
intracellular ion imbalance, cell volume dysregulation,
and balloon degeneration.
Prior observations that LLP-1 can bind to intracellular sig-
naling molecules, such as calmodulin to ultimately
induce apoptosis and/or necrosis [161,178-180] suggest
that the LLP domains may be configured in certain situa-
tions as a pore passing through the membrane and part of
their time associated with the inner leaflet of the lipid
membrane where they are able to interact with these intra-
cellular molecules. Flip-flopping between lipid bilayers of
amphipathic pore forming peptides has been docu-
mented with melittin [208,209]. Based on reported simi-
larities between melittin and LLP peptides, it is reasonable
to hypothesize that the LLP domains may be flip-flopping
between a transmembrane state and parallel association
with the inner leaflet of the lipid bilayer. On the other
hand, the LLP domains may possess different activities in
the different cell types that it infects, or there may be some
as of yet undefined temporal control that allows these two
alternate functions to take place at appropriate times dur-
ing infection.
Since the LLP domains are also present in the context of
the virion, it is possible that they would have an effect at
this stage of the HIV replication cycle. There is at least one
report of an increase in natural endogenous reverse tran-
scription (NERT) cause by the LLP domains increasing the
virion envelope permeability to dNTP's [210].
That HIV may code a viroporin in its major surface glyco-
protein would ensure that the membrane perturbation,
ion fluxes, volume changes, and resulting "loosening" of
the plasma membrane and cytoskeleton always occur
when and where it is needed for budding, syncytial forma-
tion, and/or single cell balloon degeneration. Concentrat-
ing HIV glycoproteins in lipid rafts could allow for
localized unstable membrane regions at the exact points
where it is needed by HIV. While it seems possible that
Vpu could also act at these stages to accomplish the same
goals, it is more difficult to envision how it could accom-
plish the task as Vpu has been shown to be excluded from
the plasma membrane and HIV virions [75,99].
Since SIV does not contain an equivalent of Vpu in its
genome (except SIVcpz), there is some conjecture in the lit-
erature that it utilizes its Env protein and specifically the
LLP domains of Env to take the place of Vpu in enhance-
ment of virion budding [211]. In this situation it makes
sense that deleting the LLP domains in SIV makes a more
clear cut phenotype in vivo than HIV-1. SIV minus the LLP
regions is still able to replicate, but does not cause SAIDS
[198]. It may be that the LLP domains of SIV are func-
tional equivalents of Vpu in the case of SIV. By extension,
it is possible that these two proteins represent backup sys-
tems in HIV-1 for budding, or maybe that Vpu and LLP
have specialized such that Vpu helps Env traffic through
the ER and Golgi while the LLP's increase budding more
specifically through cytoskeletal disruptions at the cell
surface. Though admittedly it is not understood to what
extent deletion of LLP domains in HIV-1 would do in vivo
since that type of controlled experiment cannot be done
ethically – truncated mutants have been found in produc-
tive human infections which cause AIDS and make it dif-
ficult to dissect the roles of these two proteins in infection
[212,213].
In addition to the LLP's involvement as a backup system
for cell volume regulation and cytoskeletal disruption,
they may produce secondary effects, such as AIDS-related
dementia complex and bystander cell death. LLP domains
could be cleaved by cellular proteases from the C-termini
of TM proteins and act as exogenous peptides for all
intents and purposes in vivo. In this way they could pro-
duce the effects generated by LLP in cell culture thought to
cause AIDS-related dementia (described above). An anal-
ogous role could be played in the death of bystander cells
– a population of cells that die in HIV-infected individu-
als, but are not productively infected [214,215].
The Lentiviral Lytic Peptide motif may not be unique to
lentiviruses, as their name would imply. Recently it was
discovered that the carboxyl termini of pestivirus enve-
lope glycoproteins contain a sequence predicted to have a
high propensity to form an amphipathic α-helix [216].
This sequence is conserved among pestiviruses. It remains
to be proven that this region of pestiviruses employ any
functional characteristics of LLP's, however it could be
hypothesized that a functional motif is beginning to show
itself. Functional substitutions of 6K protein of sindbis
virus and Vpu of HIV-1 have been proven [116]. Thus it
begs the question, could the 6K protein and LLP domains
of the E1 surface glycoprotein of sindbis virus be func-
tional equivalents of the Vpu protein and the LLP
domains of the Env surface glycoprotein of HIV-1? Func-
tional equivalents may exist in other viruses, such as the
P7 protein and LLP domains of BVDV (also a pestivirus),
as well as the VP1 and 2B proteins of poliovirus, a picor-
navirus [64,217,218].Virology Journal 2007, 4:100 http://www.virologyj.com/content/4/1/100
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In 2004 alone it was estimated that there were approxi-
mately 39.4 million people living with HIV/AIDS, with
around 3.1 million AIDS related deaths, and 13,500 new
infections each day [222]. Even with the advent of Highly
Active Anti-Retroviral Therapy (HAART), which combines
the use of protease inhibitors and reverse transcriptase
inhibitors, and use of the newer fusion inhibitors such as
T20, HIV continues to be a serious threat to world health
[219,220]. A lack of resources for most infected persons to
purchase the drugs, the intensive treatment regimen, the
toxicity of drug regiments, and emerging drug resistance
all contribute to a lack of general efficacy of the current
treatment regimen and highlight the necessity for more
basic research with the ultimate goal of development of
new treatments. The LLP domains may represent a new
target for HIV drugs to inhibit HIV infection. Otherwise
the development of eLLP's as a new class of antibacterial
drugs could be used to help resolve AIDS-related infec-
tions, as well as serve as a new class of antibiotics – virally
derived antibiotic peptides.
In order to develop the LLP domains as an attractive target
for the development of novel anti-HIV therapies, it will
likely be necessary to achieve a better understanding of
the mechanism of action of this domain. The use of bio-
chemical techniques such as oriented circular dichroism
(OCD) spectroscopy could be used to determine the ori-
entation of LLP peptides in lipid membranes, either span-
ning the membrane, lying on the surface, or somewhere in
between. Expanding on the experiments of Comardelle et
al., 1997 and continuing to define the effects of LLP pep-
tides on Xenopus oocyte membranes could also be helpful
as this system was helpful in defining the activity of the
M2 protein of influenza. Ion-selective electrodes could be
employed to characterize the ion selectivity of LLP peptide
domains. Specific LLP domain mutations could be made
to dissect each LLP domains' role in the proposed virop-
orin. Specific inhibitors of the LLP domains could be
screened for, which could help prove specific activity of
the LLP domains as a viroporin and could themselves be
a candidate for a novel class of anti-HIV drugs.
Summary of Results
Mechanisms by which HIV-1 mediates reductions in
CD4+ cell levels in infected persons are intensely investi-
gated, and have broad implications for AIDS drug and
vaccine development. Virally induced changes isn mem-
brane ionic permeability contribute to cytopathogenesis
induced by lytic viruses of many families. HIV-1 induces
disturbances in plasma membrane ion transport. The car-
boxyl terminus of TM contains amphipathic α-helical
motifs identified because of their structural similarities to
melittin, a naturally occurring cytolytic peptide, and were
dubbed lentiviral lytic peptides (LLP) -1, -2, and -3. Pep-
tides corresponding to these domains from HIV-1HXB2 (a
clade B laboratory adapted virus) partition into lipid
membranes as α-helices and disrupt model lipid mem-
branes. A peptide corresponding to the LLP-1 domain of a
clade D HIV-1 virus, dubbed LLP-1D displayed similar
activity to the LLP-1 domain of the clade B virus in all
assays, despite a lack of amino acid sequence identity.
When individual peptides are incubated exogenously with
Xenopus oocytes, LLP-1 and -2, but not LLP-3 increased the
whole cell conductance across the plasma membrane. The
increased conductance observed with LLP-1 and -2
appears to be at least in part due to an increased permea-
bility of Na+ ions. A peptide corresponding to the LLP-1
domain of a clade D HIV-1 virus, dubbed LLP-1D, dis-
played similar activity to the LLP-1 domain of the clade B
virus in all assays, despite a lack of amino acid sequence
identity.
Combinations of LLP peptides appear to act cooperatively
to increase the whole cell conductance of Xenopus oocyte
plasma membranes. Taken together, these results suggest
that the C-terminal domains of HIV-1 Env proteins may
form an ion channel, or viroporin, that is capable of con-
ducting Na+ ions. Alternatively, HIV-1 Env protein may
activate a silent Xenopus oocyte Na+-conductive ion chan-
nel. Increased understanding of the function of LLP
domains and their role in the viral replication cycle could
allow for the development of novel HIV drugs.
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